GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanc...
Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma ( Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland )
14 Oct 2019
Realising the potential of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Realising the potential of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Supporting a sustainable biosimilar solution
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Supporting a sustainable biosimilar solution ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Use of biosimilar monoclonal antibodies in the clinic
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Use of biosimilar monoclonal antibodies in the clinic ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Critical quality attributes of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Critical quality attributes of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinu...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019
IMspire170: New combination treatment for advanced melanoma
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
IMspire170: New combination treatment for advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanom...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019